The possibilities with this (fuel cell/chip) for therapy, diagnosis and ongoing treatment monitoring are very substantial. Great advancement reported by MIT Technology Review …esp. if this can enter the commercial realm! news.mit.edu/2022/glucose-f…

“Another challenge is that we’re dealing with a #RareCancer,”  Dr. Matthias Holdhoff, @Hopkinsmed talks about challenges in treating #GBM patients. Lantern gives a shoutout to @Ourbrainbank, GBM Foundation, StacheStrong and others who are advocating for #Glioblastoma patients.

HAPPENING TODAY - Join us TODAY 12PM Eastern time for #BrainTumorAwarenessMonth GBM KOL Webinar! Don't forget to register - bit.ly/3wtI0n9

$LTRN, Lantern Pharma will be attending the investor conference, The LD Micro Invitational in Westlake Village, CA focused on micro and small cap companies next week on June 7th and 8th. Our presentation will be on Tuesday - June 7th at 12:00pm Pacific / 3pm Eastern. #LDMICRO2022

When most people think of lung cancer, they often picture a smoker - But is that really the case? Check out this article by Benzinga about #NSCLC in #NeverSmokers and our Phase 2 Clinical Trial, Harmonic™️. bit.ly/3B16Xdj #Harmonic_Trial #Clinicaltrials

Study Finds New Synthetic Lethal Agent Could Be Potential Treatment for Pancreatic Cancer | Fox Chase Cancer Center - Philadelphia, PA shar.es/af7V9n

Just published by the Lantern Pharma & National Cancer Institute teams - Artificial intelligence platform, RADR® , aids in the discovery of DNA damaging agent for the ultra-rare cancer Atypical Teratoid Rhabdoid Tumors (ATRT) frontiersin.org/articles/10.33…

No one is immune from #lungcancer. Even if you never smoked. Like Sally: diagnosed w stage 4 ALK+ cancer in 2013. Thanks to research, more people like Sally are living longer. With research, we can do better. Please donate👇 donate.kindlink.com/ALK-Internatio…. #MoreResearchMoreLife #LCAM

Our teammates joined the White Ribbon 5K Race for Research virtually to support Breath of Hope Kentucky to fight lung cancer. Check out Breath of Hope Kentucky’s website and see how they are fighting #LungCancer, and ways to support! bohky.org #anyonewithlungs #WR5K4KY

November is #LungCancerAwarenessMonth. We are going to be sharing lung cancer facts, advocacy groups, patient stories, and so much more - to raise awareness of this awful disease. Make sure you #follow us for upcoming posts! #CancerAwareness #LungCancer #AnyoneWithLungs $LTRN

Never smokers represent a subgroup of patients with advanced lung cancer whose genetic makeup necessitates the need for targeted therapies and clinical trials aimed at improving outcomes. ow.ly/cnzc50LQHeF

In India, a recent study shows a 50/50 split in lung cancer diagnoses between smokers and non-smokers. Of the non-smokers, 70% are under age 50. And nearly 100% patients under 30 years of age are non-smokers. Read more 👇 indianexpress.com/article/lifest… #lcsm #ResearchSavesLives

Lantern Pharma announced positive new data for our drug candidate LP-284 for #MantleCellLymphoma (#MCL) at the ASH 2022 annual meeting. Check out the full PR here bit.ly/3YuyRYG $LTRN #ASH2022

Check out this article from Dallas Innovates by Quincy Preston - “Dallas-based Lantern Pharma is making waves in the oncology field with its #ArtificialIntelligence and #machinelearning -based drug development platform, RADR." bit.ly/3WLoWMo $LTRN

Today we’re proud to share hat the U.S. FDA granted orphan drug designation to our drug candidate LP-284 in Mantle Cell Lymphoma. Read more: bit.ly/3GiNwOe $LTRN #ODD #DrugDevelopment #MCL #MantleCellLymphoma

Lantern Pharma has received pre-IND feedback from the FDA on our clinical development plans for LP-184 program. This clears the path for the targeted initiation of a first-in-human #clinicaltrial in Q2 2023. Read more bit.ly/3kosOFl $LTRN #FDA #ClinicalResearch #Oncology

$LTRN Solid execution as they will likely get LP-184 into humans in the next six months. This is a very promising drug. Lantern still trading for close to cash on the books. Lots of upside here as they move towards clinical results. Lantern Pharma twresearchgroup.com/2023/01/lanter…

Lantern has launched a first of its kind, patient focused, iPhone app for our Phase 2 #ClinicalTrial for #neversmokers with advanced #NSCLC, the Harmonic™ trial. Download the app now apple.co/3kYtfql #ClinicalTrials $LTRN

Today, Lantern Pharma Announced Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers. Learn more here: bit.ly/3kQgxKu $LTRN #BrainCancers

Lantern Pharma will be presenting at the AACR annual meeting on April 19th, 9:00 am- 12:30pm ET. The presentation will focus on our drug candidate LP-184 and its unique mechanism of action, synthetic lethality. Check out the abstract here: bit.ly/3LjF3hU $LTRN